Abstract
Patient Focused Medicines Development (PFMD) is a not-for-profit independent multinational coalition of patients, patient stakeholders, and the pharmaceutical industry with interests across diverse disease areas and conditions. PFMD aims to facilitate an integrated approach to medicines development with all stakeholders involved early in the development process. A key strength of the coalition that differentiates it from other groups that involve patients or patient groups is that PFMD has patient organizations as founding members, ensuring that the patient perspective is the starting point when identifying priorities and developing solutions to meet patients’ needs. In addition, PFMD has from inception been formed as an equal collaboration among patient groups, patients, and pharmaceutical industry and has adopted a unique trans-Atlantic setup and scope that reflects its global intent. This parity extends to its governance model, which ensures at least equal or greater share of voice for patient group members. PFMD is actively inviting additional members and aims to expand the collaboration to include stakeholders from other sectors. The establishment of PFMD is particularly timely as patient engagement (PE) has become a priority for many health stakeholders and has led to a surge of mostly disconnected activities to deliver this. Given the current plethora of PE initiatives, an essential first step has been to determine, based on a comprehensive mapping, those strategic areas of most need requiring a focused initial effort from the perspective of all stakeholders. PFMD has identified four priority areas that will need to be addressed to facilitate implementation of PE. These are (1) culture and process change, (2) development of a global meta-framework for PE, (3) information exchange, and (4) training. This article discusses these priority themes and ongoing or planned PFMD activities within each.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Health Research Authority (HRA). Assessing professional and public opinion of the HRA. http://www.hra.nhs.uk/documents/2015/03/assessing-professional-public-opinion-hra-2015.pdf. Accessed February 13, 2016.
Key milestones of EMA interaction with patients and consumers. http://www.ema.europa.eu/ema/index.jsp?curl=pages/partners_and_networks/general/general_content_000317.jsp&mid=WC0b01ac058003500c. Accessed May 31, 2016.
EMA Press Release, December 9, 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2015/12/WC500198366.pdf. Accessed January 5, 2016.
EU Medicines Agencies Network Strategy to 2020. Working together to improve health. EMA/MB/151414/2015. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2015/12/WC500199060.pdf. Published December 17, 2015. Accessed January 5, 2016.
EMA News Release, September 21, 2015. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/09/news_detail_002394.jsp&mid=WC0b01ac058004d5c1. Accessed January 5, 2016.
EMA. Incorporating patients’ views during evaluation of benefit: risk by the EMA Scientific Committees. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/09/WC500173508.pdf. Published October 23, 2014. Accessed February 13, 2016.
About the FDA Patient Network. http://www.fda.gov/forpatients/about/default.htm. Accessed May 21, 2016.
Food and Drug Administration. Patient-Focused Drug Development: Disease Area Meetings Planned for Fiscal Years 2013–2017. http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm347317.htm. Accessed March 2, 2016.
Food and Drug Administration. Externally-Led Patient-Focused Drug Development Meetings. A Notice by the Food and Drug Administration. https://www.federalregister.gov/articles/2015/12/28/2015-32476/externally-led-patient-focused-drug-development-meetings. Published December 28, 2015. Accessed February 13, 2016.
Food and Drug Administration. FDA Voice. FDA Announces First-ever Patient Engagement Advisory Committee. Posted September 18, 2015. http://blogs.fda.gov/fdavoice/index.php/2015/09/fda-announces-first-ever-patient-engagement-advisory-committee/. Accessed January 5, 2016.
Center for Devices and Radiological Health (CDRH) strategic priorities for 2016–2017. http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHVisionandMission/UCM481588.pdf. Accessed February 8, 2016.
Food and Drug Administration. Califf: FDA Workforce, Data Gathering, Patient Engagement Top Priorities. http://www.meddeviceonline.com/doc/califf-fda-workforce-data-gathering-patient-engagement-top-priorities-0001. Accessed March 2, 2016.
Canadian Agency for Drugs and Technologies in Health. CADTH Common Drug Review Patient Input. https://www.cadth.ca/about-cadth/what-we-do/products-services/cdr/patient-input. Accessed March 2, 2016.
Canadian Agency for Drugs and Technologies in Health. CADTH 2015–2018 Strategic Plan. Informing choices in a new era of health care in Canada. https://www.cadth.ca/about-cadth/how-we-do-it/planning-documents. Accessed March 2, 2016.
Canadian Agency for Drugs and Technologies in Health. CADTH Scientific Advice Program. https://scientificadvice.cadth.ca/. Accessed March 2, 2016.
National Institute for Health and Care Excellence (NICE): Patient and Public Involvement Policy. https://www.nice.org.uk/about/nice-communities/public-involvement/patient-and-public-involvement-policy. Published November 2013. Accessed February 12, 2016.
European Patients’ Forum. Patient Involvement in Health Technology Assessment in Europe. Results of the EPF Survey (2013). http://www.eu-patient.eu/globalassets/projects/hta/hta-epf-final-report2013.pdf. Accessed February 12, 2016.
Hoos A, Anderson J, Boutin M, et al. Partnering with patients in the development and lifecycle of medicines: a call for action. Therapeutic Innovation & Regulatory Science. 2015;49:929–939.
National Health Council/Genetic Alliance. Advancing Meaningful Patient Engagement in Research, Development, and Review of Drugs. http://www.nationalhealthcouncil.org/sites/default/files/PatientEngagement-WhitePaper.pdf. Published September 2015. Accessed March 2, 2016.
University of Maryland Center for Excellence in Regulatory Science and Innovation (CERSI). Stakeholder Perspectives on Patient-Focused Drug Development: Insights from FDA, Patients, Industry, and Payers. 2015. http://www.pharmacy.umaryland.edu/media/SOP/wwwpharmacyumarylandedu/centers/cersievents/pfdd/mcersi-pfdd-proceedings.pdf. Accessed March 2, 2016.
Perfetto EM, Burke L, Oehrlein EM, Epstein RS. Patient-focused drug development: a new direction for collaboration. Med Care. 2015;53:9–17.
Nichols E; Institute of Medicine (US) Roundtable for the Development of Drugs and Vaccines Against AIDS. Expanding Access to Investigational Therapies for HIV Infection and AIDS: March 12–13, 1990 Conference Summary. Washington, DC: National Academies Press; 1991. 1, Historical Perspective. http://www.ncbi.nlm.nih.gov/books/NBK234129/. Accessed May 31, 2016.
EURORDIS. Mission and achievements. http://www.eurordis.org/content/mission-and-achievements. Accessed May 31, 2016.
Gamble C, Dudley L, Allam A, et al. Patient and public involvement in the early stages of clinical trial development: a systematic cohort investigation. BMJ Open. 2014;4:e005234.
Buck D, Gamble C, Dudley L, et al. From plans to actions in patient and public involvement: qualitative study of documented plans and the accounts of researchers and patients sampled from a cohort of clinical trials. BMJ Open. 2014;4:e006400.
Parkinson’s Disease Foundation (PDF) Parkinson’s Advocates in Research (PAIR) Leadership Awards. http://www.pdf.org/en/grant_funding_apt#pair. Accessed February 13, 2016.
Patient-Centered Outcomes Research Institute (PCORI). http://www.pcori.org/research-results/evaluating-our-work. Accessed February 13, 2016.
Parsons S, Starling B, Mullan-Jensen C, Tham SG, Warner K, Wever K. What do pharmaceutical industry professionals in Europe believe about involving patients and the public in research and development of medicines? A qualitative interview study. BMJ Open. 2016;6:e008928.
Code of Practice 2007. Code of practice between patients’ organisations and the healthcare industry (EU) 2007. http://www.eurordis.org/sites/default/files/thumbnails/0904-PO-Code%20of%20practice.pdf. Accessed March 2, 2016.
EFPIA Code of practice on relationships between the pharmaceutical industry and patient organisations 2011. http://transparency.efpia.eu/uploads/Modules/Documents/code_po2011.pdf. Accessed March 2, 2016.
IFPMA Code of Practice 2012. http://www.ifpma.org/resource-centre/ifpma-code-of-practice/. Accessed March 2, 2016.
Smith SK, Selig W, Harker M, et al. Patient engagement practices in clinical research among patient groups, industry, and academia in the United States: a survey. PLoS One. 2015;10:e0140232.
Gallin EK, Bond E, Califf RM, et al. Forging stronger partnerships between academic health centers and patient-driven organizations. Acad Med. 2013;88:1220–1224.
Merrill Corporation, BayBio. Successful public-private partnerships: a guide to effective patient foundation and life science industry collaborations. White paper. http://bit.ly/1C5mqnH. Published 2013. Accessed March 2, 2016.
Dewulf L. Patient engagement by pharma—why and how? A framework for compliant patient engagement. Therapeutic Innovation & Regulatory Science. 2015;49:9–16.
Clinical Trials Transformation Initiative (CTTI) Patient Groups & Clinical Trials (PGCT) Project. CTTI recommendations: effective engagement with patient groups around clinical trials. http://www.ctti-clinicaltrials.org/files/PatientGroups/PGCTrecs.pdf. Released October 2015. Accessed January 5, 2016.
Patient-Centered Outcomes Research Institute (PCORI) Engagement Rubric. http://www.pcori.org/sites/default/files/Engagement-Rubric.pdf. Published February 4, 2014. Updated October 13, 2015. Accessed January 24, 2016.
British Medical Journal 2014. Partnering With Patients Campaign. http://www.bmj.com/campaign/patient-partnership. Accessed January 5, 2016.
Richards T, Snow R, Schroter S. Logging the BMJ’s “patient journey.” BMJ. 2015;351:h4396.
De Wit MP, Berlo SE, Aanerud GJ, et al. European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects. Ann Rheum Dis. 2011;70:722–726.
Parsons S, Starling B, Mullan-Jensen C, et al. What the public knows and wants to know about medicines research and development: a survey of the general public in six European countries. BMJ Open. 2015;5:e006420.
Parent Project Muscular Dystrophy (PPMD). PPMD Submits Results of Patient-Centered Benefit-Risk Assessment Study in Duchenne & Becker to FDA. http://community.parentprojectmd.org/profiles/blogs/ppmd-submits-results-of-patient-centered-benefit-risk-assessment-?xg_source=Connect_news. Accessed January 26, 2016.
Food and Drug Administration. FDA issues draft guidance on developing drugs for Duchenne Muscular Dystrophy. http://www.fda.gov/Drugs/DrugSafety/ucm448894.htm. Accessed March 2, 2016.
Jakab Z. The future of health care in Europe. Presented at The Economist Conference Geneva, Switzerland. http://www.euro.who.int/__data/assets/pdf_file/0010/135586/RD_speech_Economist_20110317.pdf. Published March 17, 2011. Accessed March 2, 2016.
Wicks P, Vaughan T, Heywood J. Subjects no more: what happens when trial participants realize they hold the power? BMJ. 2014;348:g368.
The Future of Healthcare in Europe. Meeting future challenges: key issues in context Policy briefing. file:///C:/Users/ifydell/Documents/work%202015/PFMD/Priority%20pub/priority%20pub%20refs/FHE_FINAL_online.pdf. Accessed March 2, 2016.
Health Policy Brief: Patient Engagement. Health Affairs, February 14, 2013. http://www.healthaffairs.org/healthpolicybriefs/brief.php?brief_id=86. Accessed March 2, 2016.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Boutin, M., Dewulf, L., Hoos, A. et al. Culture and Process Change as a Priority for Patient Engagement in Medicines Development. Ther Innov Regul Sci 51, 29–38 (2017). https://doi.org/10.1177/2168479016659104
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479016659104